Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

Key Inclusion Criteria:

- Subject has provided informed consent

- Male or female, ≥ 18 to ≤ 85 years

- History of chronic HF (defined as requiring treatment for HF for a minimum of 30 days
before randomization)

- LVEF ≤ 35%, per subjects most recent medical record, within 12 months prior to
screening.

- NYHA class II to IV at most recent screening assessment.

- Managed with HF SoC therapies consistent with regional clinical practice guidelines
according to investigator judgment of subject's clinical status

- Current hospitalization with primary reason of HF OR one of the following events
within 1 year of screening: hospitalization with primary reason of HF; urgent visit to
emergency department (ED) with primary reason of HF.

- Elevated BNP or NT-proBNP

Other Inclusion Criteria May apply

Key Exclusion Criteria:

- Currently receiving treatment in another investigational device or drug study, or < 30
days since ending treatment on another investigational device or drug study(ies).
Other investigational procedures while participating in this study are excluded.

- Malignancy within 5 years prior to randomization with the following exceptions:
localized basal or squamous cell carcinoma of the skin, cervical intraepithelial
neoplasia, stage 1 prostate carcinoma, breast ductal carcinoma in situ.

- Subject has known sensitivity to any of the products or components to be administered
during testing

Other Exclusion Criteria May apply